Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors

Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Gregory Ravizzini(The University of Texas MD Anderson Cancer Center)

Clinical Cancer Research

August 18, 2020

10.1158/1078-0432.ccr-20-0037

Cited by 29

Related Papers

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

|Cancer Discovery|2023|115

Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures

|PLoS ONE|2011|69

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

|Clinical Cancer Research|2023|40